Melissano Germano, Bertoglio Luca, Civilini Efrem, Marone Enrico Maria, Calori Giliola, Setacci Francesco, Chiesa Roberto
Department of Vascular Surgery, Vita - Salute University, Scientific Institute H. San Raffaele, Milan, Italy.
J Endovasc Ther. 2007 Apr;14(2):150-7. doi: 10.1177/152660280701400206.
To compare the results of thoracic endovascular grafting of different aortic segments performed with commercially available stent-grafts.
Between January 1999 and October 2006, 178 patients (150 men; mean age 69.4+/-10.2 years) underwent endovascular grafting of the thoracic aorta (68 hybrid procedures) with commercially produced stent-grafts from 4 manufacturers. Patients were divided into 3 groups according to the aortic segment involved: 64 aortic arch cases (37 hybrids for supra-aortic trunks revascularization), 100 descending thoracic aorta (DTA) cases (17 hybrid: 12 for access and 5 for associated abdominal aortic aneurysm), and 14 thoracoabdominal aorta (TaA) patients excluded from conventional repair (14 hybrids for renal and splanchnic revascularization).
The technical success was 93.8% (167/178). Overall 30-day mortality was 5.6% (10/178). There were 10 (5.6%) type I endoleaks. Initial clinical success was 88.2% (157/178). At a mean follow-up of 29.3+/-21.2 months, the midterm clinical success was 89.9% (160/178). In the arch group, the technical success was 85.9% (55/64). Thirty-day mortality was 6.3% (4/64). There were 8 (12.5%) type I endoleaks. Initial and midterm clinical success rates were 79.7% (51/64) and 85.9% (55/64), respectively. In the 100-patient DTA group, the technical success was 98.0%. Thirty-day mortality was 2.0%. The type I endoleak rate was 2.0%. Clinical success was 96.0% initially and 95.0% at midterm. All 14 of the TaA cases were completed successfully, but 30-day mortality was 28.6% (4/14). There were no type I endoleaks. Clinical success rates initially and at midterm were both 71.4% (10/14).
Over the last 6 years, synergy between endovascular and surgical procedures allowed treatment of all segments of the thoracic aorta. Overall perioperative and medium-term results were reasonably favorable; however, they were more satisfactory when the descending thoracic aorta alone was involved. Hybrid procedures allowed treatment of all aortic segments, but they decreased the success rates significantly. Endovascular grafting is currently our preferred method of treating pathologies involving the DTA and aortic arch, while our data suggest limiting the use of stent-grafts to high-risk patients or compassionate indications when the thoracoabdominal aorta is involved.
比较使用市售覆膜支架对不同主动脉节段进行胸主动脉腔内修复术的结果。
1999年1月至2006年10月,178例患者(150例男性;平均年龄69.4±10.2岁)接受了使用4家制造商生产的市售覆膜支架对胸主动脉进行的腔内修复术(68例杂交手术)。根据受累主动脉节段将患者分为3组:64例主动脉弓病例(37例为主动脉弓上血管重建的杂交手术),100例降主动脉(DTA)病例(17例杂交手术:12例用于入路,5例用于合并腹主动脉瘤),以及14例被排除在传统修复之外的胸腹主动脉(TaA)患者(14例为肾和内脏血管重建的杂交手术)。
技术成功率为93.8%(167/178)。30天总死亡率为5.6%(10/178)。有10例(5.6%)I型内漏。初始临床成功率为88.2%(157/178)。平均随访29.3±21.2个月时,中期临床成功率为89.9%(160/178)。在主动脉弓组,技术成功率为85.9%(55/64)。30天死亡率为6.3%(4/64)。有8例(12.5%)I型内漏。初始和中期临床成功率分别为79.7%(51/64)和85.9%(55/64)。在100例患者的DTA组中,技术成功率为98.0%。30天死亡率为2.0%。I型内漏率为2.0%。临床成功率初始为96.0%,中期为95.0%。所有14例TaA病例均成功完成,但30天死亡率为28.6%(4/14)。无I型内漏。初始和中期临床成功率均为71.4%(10/14)。
在过去6年中,腔内和外科手术之间的协同作用使胸主动脉的所有节段都能得到治疗。围手术期和中期总体结果较为理想;然而,当仅累及降主动脉时结果更令人满意。杂交手术能治疗所有主动脉节段,但显著降低了成功率。腔内修复术目前是我们治疗累及DTA和主动脉弓病变的首选方法,而我们的数据表明,当累及胸腹主动脉时,将覆膜支架的使用限制于高危患者或出于同情性适应证。